These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19118070)

  • 1. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
    Ribas A; Comin-Anduix B; Economou JS; Donahue TR; de la Rocha P; Morris LF; Jalil J; Dissette VB; Shintaku IP; Glaspy JA; Gomez-Navarro J; Cochran AJ
    Clin Cancer Res; 2009 Jan; 15(1):390-9. PubMed ID: 19118070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
    Speeckaert R; Vermaelen K; van Geel N; Autier P; Lambert J; Haspeslagh M; van Gele M; Thielemans K; Neyns B; Roche N; Verbeke N; Deron P; Speeckaert M; Brochez L
    Eur J Cancer; 2012 Sep; 48(13):2004-11. PubMed ID: 22033321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
    Huang RR; Jalil J; Economou JS; Chmielowski B; Koya RC; Mok S; Sazegar H; Seja E; Villanueva A; Gomez-Navarro J; Glaspy JA; Cochran AJ; Ribas A
    Clin Cancer Res; 2011 Jun; 17(12):4101-9. PubMed ID: 21558401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
    Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
    Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
    Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
    Comin-Anduix B; Lee Y; Jalil J; Algazi A; de la Rocha P; Camacho LH; Bozon VA; Bulanhagui CA; Seja E; Villanueva A; Straatsma BR; Gualberto A; Economou JS; Glaspy JA; Gomez-Navarro J; Ribas A
    J Transl Med; 2008 May; 6():22. PubMed ID: 18452610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma.
    Ryu HS; Park YS; Park HJ; Chung YR; Yom CK; Ahn SH; Park YJ; Park SH; Park SY
    Thyroid; 2014 Aug; 24(8):1232-40. PubMed ID: 24742251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study.
    Niinisalo P; Oksala N; Levula M; Pelto-Huikko M; Järvinen O; Salenius JP; Kytömäki L; Soini JT; Kähönen M; Laaksonen R; Hurme M; Lehtimäki T
    Ann Med; 2010; 42(1):55-63. PubMed ID: 19941414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment.
    Furuzawa-Carballeda J; Lima G; Uribe-Uribe N; Avila-Casado C; Mancilla E; Morales-Buenrostro LE; Pérez-Garrido J; Pérez M; Cárdenas G; Llorente L; Alberú J
    Transplant Proc; 2010 Nov; 42(9):3489-96. PubMed ID: 21094802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
    Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
    Kobayashi N; Kubota K; Kato S; Watanabe S; Shimamura T; Kirikoshi H; Saito S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A
    Pancreatology; 2010; 10(5):631-40. PubMed ID: 21051918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through Foxp3+CD4+CD25+ T cells in peripheral blood.
    Ikemoto T; Shimada M; Komatsu M; Yamada S; Saito Y; Mori H; Morine Y; Imura S; Bando Y; Utsunomiya T
    Pancreas; 2013 Jan; 42(1):130-4. PubMed ID: 22722263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma.
    de Jong RA; Kema IP; Boerma A; Boezen HM; van der Want JJ; Gooden MJ; Hollema H; Nijman HW
    Gynecol Oncol; 2012 Sep; 126(3):474-80. PubMed ID: 22668882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of the anti-CTLA-4 antibody tremelimumab.
    Ribas A
    Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indoleamine 2,3-dioxygenase and foxp3 expression in skin rejection of human hand allografts.
    Hautz T; Brandacher G; Zelger B; Müller HG; Lee AW; Fuchs D; Margreiter R; Schneeberger S
    Transplant Proc; 2009 Mar; 41(2):509-12. PubMed ID: 19328914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
    Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
    Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
    Chevolet I; Speeckaert R; Haspeslagh M; Neyns B; Krüse V; Schreuer M; Van Gele M; Van Geel N; Brochez L
    Br J Dermatol; 2014 Nov; 171(5):987-95. PubMed ID: 24814041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
    Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
    BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
    Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
    Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
    Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
    Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.